



**CPAL**

Central Pennsylvania Alliance Laboratory

**Technical Bulletin**

**No. 86**

**December 2, 2010**

## **KRAS Mutation Assay Change**

**Contact:**

Dr. Jeffrey Wisotzkey, 717-851-1422  
*Technical Director, CPAL*

Jill Johns, MT(ASCP), SH, QCYM, 717-851-4320  
*Operations Manager, CPAL*

**Effective Date:** 12/06/2010

**Summary:** Effective immediately the KRAS Mutational Assay will interrogate codons 12 and 13. Codon 61 will no longer be included in the assay. Codon 61 mutations are rare and the current clinical utility for codon 61 mutational analyses is not well characterized. Should further clinical data become available in support of the analysis of this codon region of the KRAS gene, CPAL will consider re-instituting this portion of the assay.

Specific questions or concerns may be addressed to Dr. Wisotzkey